[P02BB01, trichlorfon, The therapeutic efficacy of Amantadine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01GA01, streptomycin, Amantadine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01CG01, sulbactam, Amantadine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AL01, sulpiride, The therapeutic efficacy of Amantadine can be decreased when used in combination with Sulpiride.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06DA01, tacrine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Amantadine.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Amantadine.]
[B01AE07, dabigatran etexilate, Amantadine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Tetrabenazine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Amantadine.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A11DA01, thiamine, The serum concentration of Amantadine can be increased when it is combined with Thiamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01AC01, thiotepa, The therapeutic efficacy of Amantadine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Amantadine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The therapeutic efficacy of Amantadine can be decreased when used in combination with Thiothixene.]
[B02AB01, aprotinin, The therapeutic efficacy of Amantadine can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, Amantadine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Amantadine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Amantadine is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Amantadine.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01AA12, tobramycin, Amantadine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V04CA01, tolbutamide, Amantadine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Amantadine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Amantadine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Amantadine is combined with Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Amantadine can be decreased when used in combination with Demecarium.]
[A16AX12, trientine, Amantadine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Amantadine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Amantadine.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Amantadine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Amantadine is combined with Trimethaphan.]
[J01EA01, trimethoprim, The serum concentration of Amantadine can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Amantadine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Amantadine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Amantadine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Vilazodone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Tropicamide is combined with Amantadine.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Amantadine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Amantadine is combined with Tubocurarine.]
[R03DX07, roflumilast, Amantadine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Amantadine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, The therapeutic efficacy of Amantadine can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Vandetanib.]
[R02AA14, oxyquinoline, Amantadine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Amantadine.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Rilpivirine.]
[S01AA28, vancomycin, Amantadine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ezogabine.]
[B01AF01, rivaroxaban, Amantadine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Amantadine.]
[N06AX09, viloxazine, Amantadine may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[B01AA03, warfarin, Amantadine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Amantadine can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Amantadine.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amantadine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Amantadine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Amantadine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Amantadine can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Amantadine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amantadine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Amantadine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Amantadine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Tolterodine.]
[J01DH04, doripenem, Amantadine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Amantadine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Amantadine is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Amantadine.]
[M01CB03, auranofin, Amantadine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Amantadine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Amantadine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Amantadine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Amantadine.]
[A08AA11, lorcaserin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mirabegron.]
[L02BB04, enzalutamide, Amantadine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Amantadine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Barbital.]
[D02BA02, octinoxate, Amantadine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Amantadine.]
[N04BD02, rasagiline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Mosapride.]
[N06DA02, donepezil, The therapeutic efficacy of Amantadine can be decreased when used in combination with Donepezil.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Amantadine.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Amantadine is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Amantadine.]
[V09IX04, fluorodeoxyglucose F18, Amantadine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pasireotide.]
[V08CA11, gadofosveset, Amantadine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Amantadine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Bencyclane.]
[A10BH04, alogliptin, Amantadine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Amantadine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Amantadine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Tegaserod.]
[L03AA12, ancestim, Amantadine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Amantadine.]
[L01EC02, dabrafenib, The serum concentration of Amantadine can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01EE01, trametinib, Amantadine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Amantadine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The serum concentration of Amantadine can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Bepridil.]
[A10BJ03, lixisenatide, Amantadine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Amantadine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AP08, sofosbuvir, Amantadine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Amantadine may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Amantadine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Amantadine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Amantadine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Betaine.]
[V03AB34, fomepizole, Amantadine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Amantadine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[D11AA01, glycopyrronium, Amantadine may increase the anticholinergic activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V04CX03, methacholine, Amantadine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Amantadine.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Amantadine is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Amantadine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Amantadine.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Amantadine.]
[B01AF03, edoxaban, Amantadine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Amantadine may increase the serotonergic activities of Mirtazapine.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Amantadine.]
[L01EX08, lenvatinib, The serum concentration of Amantadine can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Amantadine is combined with Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Amantadine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Amantadine can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Amantadine.]
[N05AX15, cariprazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Amantadine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Amantadine can be increased when it is combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amantadine.]
[L01XG03, ixazomib, Amantadine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Amantadine.]
[M04AB05, lesinurad, Amantadine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N03AX23, brivaracetam, Amantadine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Amantadine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[A02AD05, aluminum magnesium silicate, Amantadine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amantadine.]
[N06AA19, amineptin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Amineptine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Amantadine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Bupranolol.]
[N07BC01, buprenorphine, The risk or severity of adverse effects can be increased when Amantadine is combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Amantadine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Artemether.]
[M02AA03, clofezone, Amantadine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Amantadine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Amantadine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Amantadine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R03CC12, bambuterol, The therapeutic efficacy of Amantadine can be decreased when used in combination with Bambuterol.]
[A06AH05, naldemedine, Amantadine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Amantadine.]
[P01CA02, benznidazole, Amantadine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Amantadine.]
[J05AF06, abacavir, Amantadine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[N07XX13, valbenazine, Amantadine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Amantadine is combined with Acetylcholine.]
[L01BC06, capecitabine, Amantadine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The serum concentration of Amantadine can be increased when it is combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Vorinostat.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Amantadine.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Amantadine is combined with Bornaprine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Amantadine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The therapeutic efficacy of Amantadine can be decreased when used in combination with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Amantadine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Amantadine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Amantadine.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Amantadine is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Carbinoxamine.]
[N03AX24, cannabidiol, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Cannabidiol.]
[L04AA37, baricitinib, Amantadine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01GB14, plazomicin, Amantadine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Amantadine can be increased when it is combined with Tafenoquine.]
[A16AX14, migalastat, Amantadine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Amantadine may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Amantadine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Amantadine.]
[D08AE05, chloroxylenol, Amantadine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Amantadine is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Inotersen.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Amantadine is combined with Revefenacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Amantadine.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Amifampridine.]
[A06AX05, prucalopride, Amantadine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Cinitapride.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Amantadine.]
[L01EN01, erdafitinib, The serum concentration of Amantadine can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Amantadine.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Cyclobenzaprine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Entrectinib.]
[N07XX11, pitolisant, Amantadine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Amantadine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Amantadine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Amantadine.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M09AX08, golodirsen, Amantadine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amantadine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Amantadine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Amantadine is combined with Dezocine.]
[N05AD10, lumateperone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Lumateperone.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Gatifloxacin.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Frovatriptan.]
[R02AA03, dichlorobenzyl alcohol, Amantadine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Amantadine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Amantadine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Eletriptan is combined with Amantadine.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08CA16, clevidipine, Amantadine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The serum concentration of Amantadine can be increased when it is combined with Tucatinib.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Amantadine is combined with Dihexyverine.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Amantadine.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V08CA05, mangafodipir, Amantadine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fostemsavir.]
[N02AX07, oliceridine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The serum concentration of Amantadine can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Amantadine can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Amantadine.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Amantadine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[V03AF12, trilaciclib, The serum concentration of Amantadine can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Flumequine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02BG07, flupirtine, Amantadine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Amantadine.]
[A02BA01, cimetidine, The serum concentration of Amantadine can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Amantadine.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Amantadine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Amantadine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Amantadine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Amantadine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Clemastine.]
[N06AX25, St. John's wort extract, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with St. John's Wort.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Amantadine.]
[N01BB10, levobupivacaine, Amantadine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Amantadine can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Clomipramine.]
[N03AE01, clonazepam, Amantadine may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Amantadine.]
[A04AA02, granisetron, The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Amantadine.]
[N05AH02, clozapine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Clozapine.]
[J01GB12, arbekacin, Amantadine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Amantadine is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Amantadine is combined with Hexafluronium.]
[M04AC01, colchicine, Amantadine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Amantadine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Amantadine.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Amantadine is combined with Homatropine.]
[J01XB01, colistin, Amantadine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Desflurane.]
[A04AA03, tropisetron, Amantadine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Telithromycin.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Desloratadine.]
[J05AB14, valganciclovir, Amantadine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Amantadine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Amantadine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Amantadine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Amantadine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Amantadine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[H01AX01, pegvisomant, The therapeutic efficacy of Amantadine can be decreased when used in combination with Pegvisomant.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Amantadine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Emedastine.]
[N05BA10, ketazolam, Amantadine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Amantadine.]
[N03AX09, lamotrigine, The serum concentration of Amantadine can be increased when it is combined with Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levocabastine.]
[N07BC04, lofexidine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AX13, loratadine, Amantadine may increase the anticholinergic activities of Loratadine.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Amantadine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Amantadine is combined with Mebeverine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Amantadine.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The therapeutic efficacy of Amantadine can be decreased when used in combination with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Amantadine is combined with Cyclopentolate.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AX07, minaprine, The risk or severity of serotonin syndrome can be increased when Minaprine is combined with Amantadine.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AG02, moclobemide, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Amantadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Amantadine.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Amantadine is combined with Cytarabine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Amantadine.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N07BB05, nalmefene, Amantadine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Nefazodone.]
[C01DX16, nicorandil, Amantadine may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Amantadine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Amantadine is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AA01, desipramine, The serum concentration of Amantadine can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V04CH02, indigo carmine, Amantadine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Amantadine.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Amantadine is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Amantadine is combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Amantadine.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Amantadine.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with Amantadine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Amantadine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Amantadine.]
[B01AC04, clopidogrel, The serum concentration of Amantadine can be increased when it is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Amantadine is combined with Diamorphine.]
[P03AC04, permethrin, Amantadine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AA08, dibenzepin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Dibenzepin.]
[S02DA04, dibucaine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Cinchocaine.]
[R05DA08, pholcodine, Amantadine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Amantadine.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Amantadine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Amantadine is combined with Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Amantadine.]
[D07XC04, diflucortolone, Amantadine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Amantadine is combined with Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Digitoxin.]
[C01AA05, digoxin, Amantadine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Amantadine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Amantadine is combined with Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Amantadine.]
[H03BC01, potassium perchlorate, Amantadine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Amantadine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Amantadine is combined with Dimetindene.]
[M02AX03, dimethyl sulfoxide, Amantadine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G02AD02, dinoprostone, The serum concentration of Amantadine can be increased when it is combined with Dinoprostone.]
[R06AA02, diphenhydramine, The serum concentration of Amantadine can be increased when it is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Amantadine is combined with Diphenoxylate.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amantadine.]
[N06AA23, quinupramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Cisapride.]
[S01AX06, resorcinol, Amantadine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Amantadine.]
[N05AX08, risperidone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levocetirizine.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Amantadine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amantadine.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01EB18, ranolazine, The serum concentration of Amantadine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R03AC12, salmeterol, The serum concentration of Amantadine can be increased when it is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Domperidone.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Amantadine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Amantadine.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Amantadine.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sevoflurane.]
[N05AD08, droperidol, The therapeutic efficacy of Amantadine can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Amantadine.]
[A12CA02, sodium sulfate, Amantadine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of serotonin syndrome can be increased when Sumatriptan is combined with Amantadine.]
[V04CX07, edrophonium, The therapeutic efficacy of Amantadine can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Terodiline.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Amantadine is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Tianeptine.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Amantadine.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Amantadine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Amantadine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Triptorelin.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Amantadine is combined with Tropatepine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Amantadine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Amantadine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Venlafaxine.]
[S01EA01, epinephrine, The serum concentration of Amantadine can be increased when it is combined with Epinephrine.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Amantadine.]
[N05AX11, zotepine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Amantadine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Amantadine.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of serotonin syndrome can be increased when Ergotamine is combined with Amantadine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Valproic acid.]
[L03AX05, pidotimod, Amantadine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Erythromycin.]
[N05CD04, estazolam, Amantadine may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G03CA03, estradiol, The serum concentration of Amantadine can be increased when it is combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Gepefrine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ibutilide.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Amantadine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Amantadine.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Amantadine is combined with Ethylmorphine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AE03, sertindole, The therapeutic efficacy of Amantadine can be decreased when used in combination with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Amantadine.]
[A02BA04, nizatidine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Terfenadine.]
[P01AX07, trimetrexate, Amantadine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The excretion of Amantadine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Fluvoxamine is combined with Amantadine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Leuprolide.]
[M01CB01, gold sodium thiomalate, Amantadine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Amantadine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A02BA03, famotidine, The serum concentration of Amantadine can be increased when it is combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Amantadine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Amantadine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Amantadine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Amantadine is combined with Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Amantadine.]
[J02AX01, flucytosine, Amantadine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Amantadine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N06AA14, melitracen, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Melitracen.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Amantadine.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Amantadine can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Fluphenazine.]
[N05CD01, flurazepam, The serum concentration of Amantadine can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01BC03, tegafur, Amantadine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Amantadine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Amantadine.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AL05, amisulpride, The therapeutic efficacy of Amantadine can be decreased when used in combination with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Amantadine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Amantadine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Amantadine is combined with Ganciclovir.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Bifemelane.]
[C10AB04, gemfibrozil, Amantadine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Amantadine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Amantadine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Lapatinib.]
[A10BB07, glipizide, Amantadine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Amantadine.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Amantadine.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Amantadine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Amantadine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Amantadine.]
[M01CB04, aurothioglucose, Amantadine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Amantadine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01EX01, guanethidine, Amantadine may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Amantadine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Amantadine.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Amantadine.]
[G03DC01, allylestrenol, Amantadine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Amantadine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Hexobarbital.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Amantadine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Oxatomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02DB02, hydralazine, Amantadine may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Amantadine.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Amantadine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Amantadine is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Amantadine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Hydroxyzine.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[B05XA08, sodium acetate, Amantadine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Amantadine.]
[L01AA06, ifosfamide, Amantadine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Amantadine is combined with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Amantadine can be increased when it is combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Terlipressin.]
[R01AD07, tixocortol, Amantadine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Amantadine.]
[L01CE01, topotecan, Amantadine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Amantadine.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A11HA07, inositol, Amantadine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Amantadine is combined with Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Amantadine.]
[A10BH01, sitagliptin, Amantadine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05CH02, ramelteon, Amantadine may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Amantadine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Anagrelide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Amantadine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Amantadine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Amantadine can be decreased when used in combination with Isoflurophate.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Isoniazid.]
[J05AX05, inosine pranobex, Amantadine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The therapeutic efficacy of Amantadine can be decreased when used in combination with Isoprenaline.]
[C01DA14, isosorbide mononitrate, Amantadine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Amantadine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[S01AA24, kanamycin, Amantadine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Ketamine.]
[C02KD01, ketanserin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Ketanserin.]
[B01AC22, prasugrel, Amantadine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Amantadine can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mizolastine.]
[N04BC09, rotigotine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pipemidic acid.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Amantadine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nalidixic acid.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Amantadine.]
[N07AA30, ambenonium, The therapeutic efficacy of Amantadine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, Amantadine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Lidoflazine.]
[S01AA21, amikacin, Amantadine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, The serum concentration of Amantadine can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of serotonin syndrome can be increased when Lisuride is combined with Amantadine.]
[N06AA07, lofepramine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AH01, loxapine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Loxapine.]
[B05XA11, magnesium chloride, Amantadine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Amantadine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Amantadine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Amantadine.]
[L01BA05, pralatrexate, Amantadine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Amantadine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Amantadine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Amantadine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Amantadine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Amantadine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Amantadine is combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Amantadine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Mephentermine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amantadine.]
[N01BB03, mepivacaine, Amantadine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Amantadine is combined with Meptazinol.]
[G04BX16, tiopronin, Amantadine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Paliperidone.]
[A10BA02, metformin, The serum concentration of Amantadine can be increased when it is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Amantadine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Amantadine is combined with Methadone.]
[N06BA03, methamphetamine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Amantadine is combined with Methantheline.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Amantadine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Amantadine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Methimazole may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L01BA04, pemetrexed, Amantadine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Amantadine.]
[C02AB01, methyldopa, Amantadine may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Amantadine may increase the serotonergic activities of Methylene blue.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.]
[G03EK01, methyltestosterone, Amantadine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The serum concentration of Amantadine can be increased when it is combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Metronidazole.]
[V04CD01, metyrapone, Amantadine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Mianserin.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Amantadine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Lisdexamfetamine.]
[N05AE02, molindone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of serotonin syndrome can be increased when Amitriptyline is combined with Amantadine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Amantadine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Amantadine.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Amantadine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Amantadine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, Amantadine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Amantadine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Amantadine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Amantadine.]
[C07AA12, nadolol, Amantadine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CA04, amoxicillin, Amantadine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Amantadine is combined with Nalbuphine.]
[V03AB15, naloxone, Amantadine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Amantadine is combined with Naltrexone.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Amantadine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Amantadine.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S03AA01, neomycin, Amantadine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Amantadine is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01EB06, neostigmine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The therapeutic efficacy of Amantadine can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[L03AX16, plerixafor, Amantadine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Amantadine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CE01, inamrinone, Amantadine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Amantadine.]
[N07BA01, nicotine, The serum concentration of Amantadine can be increased when it is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nimodipine.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05CF03, zaleplon, Amantadine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Amantadine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01CA03, norepinephrine, The serum concentration of Amantadine can be increased when it is combined with Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Norfloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Amantadine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amantadine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ofloxacin.]
[N06AA05, opipramol, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Amantadine is combined with Opium.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The serum concentration of Amantadine can be increased when it is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Amantadine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Amantadine is combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Amantadine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Amantadine can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Asenapine.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Amantadine is combined with Tapentadol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Amantadine is combined with Pancuronium.]
[J04AB30, capreomycin, Amantadine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Papaverine.]
[C02KC01, pargyline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Amantadine.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Amantadine is combined with Fesoterodine.]
[C07AA23, penbutolol, Amantadine may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Amantadine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Amantadine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Amantadine.]
[L01XX08, pentostatin, Amantadine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Perhexiline.]
[N05AB03, perphenazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Amantadine is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Amantadine.]
[A10BA01, phenformin, The serum concentration of Amantadine can be increased when it is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Pheniramine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Amantadine is combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Amantadine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Amantadine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The serum concentration of Amantadine can be increased when it is combined with Phenoxybenzamine.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Amantadine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Physostigmine.]
[B02BA01, vitamin K1, Amantadine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Amantadine can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Amantadine.]
[N06BX03, piracetam, Amantadine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Amantadine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Amantadine is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pizotifen.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Amantadine.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Amantadine.]
[A10BH03, saxagliptin, Amantadine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Prajmaline.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Amantadine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Amantadine.]
[M04AB01, probenecid, The serum concentration of Amantadine can be increased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Probucol.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Amantadine.]
[S01HA05, procaine, The risk or severity of serotonin syndrome can be increased when Procaine is combined with Amantadine.]
[L01XB01, procarbazine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Procarbazine.]
[C10AB05, fenofibrate, Amantadine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Amantadine.]
[G03DA04, progesterone, The serum concentration of Amantadine can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Propafenone.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Amantadine.]
[N05AC01, periciazine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Amantadine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Amantadine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Amantadine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Amantadine can be increased when it is combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Rizatriptan.]
[B01AC09, epoprostenol, Amantadine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Amantadine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Amantadine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Amantadine.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Amantadine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Amantadine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Amantadine is combined with Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Amantadine.]
[P02CC01, pyrantel, Amantadine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Mepyramine.]
[P01AX05, quinacrine, The serum concentration of Amantadine can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, Amantadine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Amantadine can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Amantadine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Amantadine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Amantadine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Amantadine.]
[N04BD01, selegiline, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Selegiline.]
[J01GB08, sisomicin, Amantadine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Amantadine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Amantadine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Amantadine.]
